Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.81 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30689554 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL7057008 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL17819377 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1132969 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1254547 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL4445694 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1744226 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL8168856 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL114922 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1179464 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | claimed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | claimed |
| US-20250212873-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-07-03 | — | — | US | disclosed |
| CN-119894387-A | Flavor modulating composition | 玉米产品开发公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4482306-A1 | VOLATILE HDAC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2023192424-A1 | VOLATILE HD AC INHIBITORS FOR THERAPEUTIC AND PLANT APPLICATIONS CROSS-REFERENCE TO RELATED APPLICATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| CN-113201511-B | (R) -5-carbonyl decanoate (ester) reductase mutant and application thereof in preparation of (R) -gamma/delta-lactone | 华东理工大学 | 2022-08-30 | — | — | CN | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | CYP1A2 4564/4885PPARG 217/4885EPHX1 3026/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CYP1A2 4564/4885PPARG 217/4885EPHX1 3026/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | CYP1A2 4564/4885PPARG 217/4885EPHX1 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.